Clinical trials: Diabetes, Type 1
Patients
Drug Interaction Study Between Dorzagliatin and Empagliflozin
This is a Phase 1, open-label, sequential, multiple-dose, drug interaction study of glucokinase activator dorzagliatin and empagliflozin in subjects with T2DM.
- Trial name
- NCT03790787
- Testing
- Empagliflozin, Dorzagliatin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Hua Medicine Limited
Diabetes Mellitus, Type 1
Patient Empowerment Through Predictive Personalised Decision Support (PEPPER)
Patient Empowerment through Predictive PERsonalised decision support (PEPPER) is an European Union (EU) funded research project to develop a personalised clinical decision support system for Type 1 Diabetes Mellitus (T1DM)…
- Trial name
- PEPPER (NCT03186300)
- Testing
- PEPPER system
- Where
- Spain
- Volunteers
- 8 people
- Sponsor
- Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Type 1 Diabetes Mellitus, Hypercalciuria
Safety and Efficacy of Chlorthalidone in Type 1 Diabetes
This open-label study will determine if chlorthalidone is safe and effective for the use of reducing urinary calcium excretion over 4 weeks in subjects with type 1 diabetes
- Trial name
- NCT03325114
- Testing
- Chlorthalidone
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Rochester
Diabetes Mellitus, Type 1
Effect of HCL Insulin Delivery System on Glycemic Control in Patients With T1D
The goal of this study is compare the effect of hybrid closed loop system (HCL) for automatic insulin dosing treatment on the glycemic control of type 1 diabetes (T1D) in patient with different initial glycated hemoglobin.
- Trial name
- NCT05924932
- Testing
- Tandem t:slim X2 with hybrid closed loop system Control IQ, glucose sensor: Dexcom G6, MiniMed 780G, with hybrid closed loop system SmartGuard, sensor Guardien 4
- Where
- Czechia
- Volunteers
- 120 people
- Sponsor
- Masaryk Hospital Usti nad Labem
Type 1 Diabetes
The iLet Experience Study
A one-year, prospective single-arm cohort study to collect safety and effectiveness data on the iLet Dosing Decision Software during real-world use in people 6 years of age or older with type 1 diabetes (T1D) with 12 months…
- Trial name
- NCT06891898
- Testing
- iLet Dosing Decision Software
- Where
- United States
- Volunteers
- 1,875 people
- Sponsor
- Beta Bionics, Inc.
Diabete Type 1, Ketoacidosis, Diabetic
Hemoglobin Levels and Resolution Time of Diabetic Ketoacidosis in Pediatric Patients
This retrospective observational cohort study aims to evaluate the association between hemoglobin levels and the time to resolution of diabetic ketoacidosis (DKA) in pediatric patients.
- Conditions
- Diabete Type 1, Ketoacidosis, Diabetic, Pediatrics, Child
- Trial name
- NCT07377604
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Aydin Adnan Menderes University
Diabetes Mellitus, Osteoporosis
Type 1 Diabetes Mellitus Effect on Bone Mineral Density
Because the diabetics are fracturing at a younger age than the general population (12), this leads us to believe there are significant factors that lead to fracture in Type 1 diabetes mellitus (DM) other than bone mineral density…
- Trial name
- NCT01633684
- Where
- United States
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Creighton University
Diabetes (Insulin-requiring, Type 1 or Type 2), Pediatric Diabetes
A Novel Miniature Equine-Assisted Diabetes Education Program for Youth: Evaluating the Diabetes Equine Empowerment Program (DEEP).
The Diabetes \& Equine Empowerment Program (DEEP) is a research study evaluating a novel diabetes education program that combines hands-on interactions with miniature horses and evidence-based diabetes self-management education…
- Conditions
- Diabetes (Insulin-requiring, Type 1 or Type 2), Pediatric Diabetes, Diabetes (DM)
- Trial name
- DEEP (NCT07822555)
- Testing
- Diabetes & Equine Empowerment Program (DEEP)
- Volunteers
- 50 people
- Sponsor
- Nemours Children's Clinic
Diabetes Mellitus, Type 1
A Study of Technology to Improve Glucose Control in Participants With Type 1 Diabetes
The main purpose of this study is to determine whether combining meal, glucose, and insulin data in a web-based system will improve management of type 1 diabetes (T1D). No study drug will be given.
- Trial name
- NCT03758430
- Testing
- Meal-Tagging App, Fitness Tracker
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Type I Diabetes
Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus
This study will examine the safety of three times weekly SC injections of OPT101 at each of three dose levels over two weeks as well as one year of treatment with SC OPT101 or placebo to match at a single dose level.
- Trial name
- NCT06964087
- Testing
- OPT101
- Where
- 5 sites in United States
- Volunteers
- 72 people
- Sponsor
- Op-T LLC
Diabetes Mellitus, Type 2
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to semaglutide taken once a week in people with type 2 diabetes.
- Trial name
- COMBINE 2 (NCT05259033)
- Testing
- IcoSema, Semaglutide 1 mg
- Where
- 193 sites in United States, Brazil and 13 more
- Volunteers
- 683 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)
The goal of this study is to determine if Hylenex recombinant leads to changes in the insulin time-action profiles and glucose responses when preadministered in the setting of continuous subcutaneous insulin infusion (CSII)…
- Trial name
- HALO-117-406 (NCT03662334)
- Testing
- Rapid Acting insulin with pre-treatment of rHuPH20
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Halozyme Therapeutics
Type 1 Diabetes, Type 2 Diabetes
Nurse Telephone Management of Cholesterol in Diabetes
The current project is evaluating the effect of a nurse-administered phone care in diabetes to improve access to care and healthcare delivery.
- Trial name
- NATCHOS (NCT00950963)
- Testing
- Phone Counseling, Standard Clinical Care
- Where
- United States
- Volunteers
- 762 people
- Sponsor
- Denver Health and Hospital Authority
Type 1 Diabetes, Diabetes
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
The main purpose of this study is to measure the safety and efficacy of insulin efsitora alfa (LY3209590) compared with insulin degludec in participants with type 1 diabetes treated with multiple daily injection therapy.
- Trial name
- QWINT-5 (NCT05463744)
- Testing
- Insulin Efsitora Alfa, Insulin Degludec
- Where
- 83 sites in United States, Argentina and 5 more
- Volunteers
- 692 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs
The investigational therapy under study in this trial, regulatory T cells (Tregs), offers the hope of stabilizing further destruction of insulin producing beta cells in type 1 diabetes.
- Trial name
- Treg (NCT01210664)
- Testing
- Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Francisco
Diabetes Mellitus, Type 1
Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents
To assess the safety and efficacy of Exubera on pulmonary function and glycemic control in subjects ages 6-17 over a 1 year period.
- Trial name
- NCT00479258
- Testing
- Inhaled insulin (Exubera), Subcutaneous Insulin (subject's prescribed)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Pfizer
Type 2 Diabetes, Type 1 Diabetes Mellitus
The Impact of the COVID-19 Pandemic on Diabetes Management
The "CoDiaM study" examines how diabetes management and outcomes are changing during the COVID-19 pandemic and whether these changes are influenced by socio-demographic factors, health literacy, self-efficacy and perceived social…
- Trial name
- CoDiaM (NCT04821921)
- Testing
- No intervention
- Where
- Germany
- Volunteers
- 1,503 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Diabetes Mellitus, Type 1 Diabetes, Mobile Health Platform
Feasibility and Effectiveness of Tele-diabetes Remote System on Glycemic Control and Quality of Life of Children and Youth With Type 1 Diabetes
The goal of this clinical trial is to examine the feasibility and effectiveness of a tele-diabetes remote monitoring system on managing type 1 diabetes (T1DM) among children and adolescents.
- Conditions
- Diabetes Mellitus, Type 1 Diabetes, Mobile Health Platform, Mobile Health Technology (mHealth), Mobile Health
- Trial name
- NCT07828106
- Testing
- Tele-diabetes Remote System
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Sheba Medical Center
Type 1 Diabetes
Monocyte Function and Inflammation in Type 1 Diabetes and Its Modulation
Type I diabetes (T1DM) is associated with an increased risk of vascular complications. While the precise mechanism(s) by which diabetes accelerates atherosclerosis has not been elucidated, several lines of evidence point to the…
- Trial name
- NCT00441844
- Testing
- Simvastatin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, Davis
Diabetes Mellitus, Type 1
ECG Changes in Children and Adolescents With Type 1 Diabetes
Diabetes Mellitus type 1 is characterized by an absolute insulin deficiency caused by T-cell-mediated autoimmune destruction of pancreatic β-cells .
- Trial name
- NCT03260998
- Testing
- electrocardiogram
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Assiut University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.